Vascular effects of serotonin and ischemia.
Circulating 5-hydroxytryptamine originates in the gastrointestinal tract, where it overflows to the blood: part of that serotonin is taken up and stored by the platelets. When the latter aggregate, the released serotonin feeds back on the platelets to amplify the aggregation process; this amplification can be blocked with 5-HT2-serotonergic antagonists such as ketanserin and naftidrofuryl. Serotonin is taken up and destroyed by the endothelial cells; these cells also release endothelium-derived relaxing factor (EDRF) when exposed to the monoamine. The release of EDRF evoked by serotonin is not blocked by 5-HT2-serotonergic antagonists and involves a pertussis toxin-sensitive G-protein. When serotonin reaches vascular smooth muscle it usually causes it to contract; this, in most blood vessels, is prevented by 5-HT2-serotonergic antagonists. The contractions evoked by serotonin are reduced considerably in the presence of a normal endothelium. The same is true for contractions evoked by aggregating platelets, which release enough serotonin to activate receptors on both the endothelial cells (release of EDRF) and on vascular smooth muscle (contraction). Thus, 5-HT2-serotonergic antagonists favor vasodilatation not only because they brake the amplifying effect that serotonin exerts on further platelet aggregation, but also because, by blocking the direct activation of the vascular smooth muscle by platelet-released serotonin, they facilitate the occurrence of endothelium-dependent relaxations to the platelet products.(ABSTRACT TRUNCATED AT 250 WORDS)
Vanhoutte
P M
PM
Baylor College of Medicine, Houston, TX 77030, USA.
D000818:Animals; D006801:Humans; D007511:Ischemia / Q000188:drug therapy*; D012701:Serotonin / Q000502:physiology*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014652:Vascular Diseases / Q000188:drug therapy*; D014661:Vasoconstriction; D014664:Vasodilation
D012702:Serotonin Antagonists; D012701:Serotonin